Compare VITL & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VITL | KMDA |
|---|---|---|
| Founded | 2007 | 1990 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 550.6M | 488.6M |
| IPO Year | 2020 | 2013 |
| Metric | VITL | KMDA |
|---|---|---|
| Price | $12.72 | $8.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 2 |
| Target Price | ★ $32.00 | $14.00 |
| AVG Volume (30 Days) | ★ 2.4M | 43.3K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | ★ 3.02% |
| EPS Growth | ★ 22.03 | N/A |
| EPS | ★ 1.44 | N/A |
| Revenue | ★ $759,444,000.00 | N/A |
| Revenue This Year | $19.72 | $13.94 |
| Revenue Next Year | $17.02 | $9.84 |
| P/E Ratio | ★ $8.76 | $24.59 |
| Revenue Growth | ★ 25.26 | N/A |
| 52 Week Low | $12.12 | $6.35 |
| 52 Week High | $53.13 | $9.35 |
| Indicator | VITL | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 36.48 | 44.41 |
| Support Level | $12.35 | $7.96 |
| Resistance Level | $14.57 | $8.50 |
| Average True Range (ATR) | 0.78 | 0.18 |
| MACD | 0.35 | -0.01 |
| Stochastic Oscillator | 33.15 | 18.37 |
Vital Farms Inc is an ethical food company. The company retails pasture-raised eggs and butter. Its products include Pasture-Raised Eggs and Pasture-Raised Butter & Ghee. The company's purpose is rooted in a commitment to Conscious Capitalism, which prioritizes the long-term benefits of its stakeholders (farmers and suppliers, customers and consumers, communities and the environment, employees, and stockholders).
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.